Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 14/20 | 0.42 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.39 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10116781 | 0.89 | GPR119 (0.49) | GPR119CYP2C9 | |
| SCHEMBL10116788 | 0.87 | GPR119 (0.50) | GPR119CYP2C9 | |
| SCHEMBL10116595 | 0.86 | GPR119 (0.55) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL10116785 | 0.81 | GPR119 (0.42) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL10116593 | 0.80 | GPR119 (0.61) | GPR119 | |
| SCHEMBL10134616 | 0.80 | GPR119 (0.47) | GPR119PIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL10116801 | 0.78 | GPR119 (0.52) | GPR119CYP2C9 | |
| SCHEMBL12277317 | 0.77 | GPR119 (0.60) | GPR119 | |
| SCHEMBL12277144 | 0.77 | GPR119 (0.51) | GPR119 | |
| SCHEMBL10116796 | 0.76 | GPR119 (0.49) | GPR119CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580807-B2 | Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders | MERCK SHARP & DOHME CORP. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | MERCK SHARP & DOHME LLC | 2012-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120021976-A1 | BICYCLIC PIPERIDINE AND PIPERAZINE DERIVATIVES AS GPCR MODULATORS FOR THE TREATMENT OF OBESITY, DIABETES AND OTHER METABOLIC DISORDERS | GPR119, GPR55, GPR4 | GPR119 1/4885PIK3CD 660/4885PIK3CA 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.